Pectolinarin Attenuates Scopolamine-Induced Synaptic Plasticity and Memory Deficits

Alzheimer's disease (AD) is characterized by memory impairment and synaptic plasticity deficits, with cholinergic dysfunction in the hippocampus playing a crucial pathological role.Scopolamine, a muscarinic acetylcholine receptor (mAChR) antagonist, is widely used to induce cognitive deficits by disrupting synaptic plasticity in the hippocampus.In this study, we investigated whether pectolinarin can attenuate long-term potentiation (LTP) impairment and memory deficits induced by scopolamine.In hippocampal slice experiments, pectolinarin significantly restored LTP that was reduced by scopolamine treatment, and this effect was abolished by IEM-1460, a selective calcium-permeable AMPAR (CP-AMPAR) antagonist.This suggests that pectolinarin enhances CP-AMPAR activity, contributing to the preservation of synaptic plasticity.Furthermore, behavioral experiments demonstrated that pectolinarin alleviated scopolamine-induced memory impairment.Our findings indicate that pectolinarin may protect synaptic plasticity and cognitive function, providing valuable insights for the development of therapeutic agents targeting neurodegenerative diseases such as AD, which are associated with cholinergic dysfunction.